phentermine-topiramate and glp-1 receptor agonists Navigating Weight Loss Medications: Long-Term Use, Discontinuation, Maintaining Weight Loss Mapping the effectiveness and risks

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

GLP-1 is a hormone that the gut produces after eating to regulate blood sugar, slow digestion and manage hunger

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

Case reports document perioperative aspiration in semaglutide users, including episodes of hypoxemia and reintubation despite guideline-concordant fasting

Medical-grade dual receptor agonist with expert physician monitoring and personalized weight loss protocols.

However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety